「in vitroinvivoin vitroinvivo」の検索結果
153件：71～75件目を表示
-
armaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for NAVIS” in Japan. MIEr for NAVIS can sharpen images on NAVIS-AZU or NAVIS-CL* by installing Logic and Design...
https://www.senju.co.jp/system/files/content_news/2024-04/ENG_20240423.pdf -
rmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., L...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
产品开发方针 | 研究与开发 | 千寿制药株式会社
人以上未得到必要的治疗。并且报告中还提到白内障、屈光不正（近视、老花眼等）、老年性黄斑变性、青光眼、糖尿病性视网膜病变等是导致全球性视力受损或失明的主要原因。 为创造针对眼部疾病的高价值（First in Class、Best in Class、提升患者便利性等）的产品，今后，我们也将全力推进研究开发活动。我们从“对导致视力受损或失明的眼部疾病的贡献”、“满足未满足的医疗需求*”、“商业化的可能性...
http://www.senju.co.jp/chinese/rd/policy/ -
nt: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmace...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
お知らせ | 千寿製薬株式会社
September 4, 2025 Senju has developed and obtained approval for a BAC-free formulation of Aibeta® combination eye drops（PDF） March 7, 2025 Announcement of Licensing Agreement with Brill International（...
https://www.senju.co.jp/english/news/